Synermore is a biotechnology company focused on the treatment of malignant tumors, dedicated to the research and development of innovative and biosimilar monoclonal antibodies in the fields of oncology, infectious diseases and immune diseases. The core competency is taking products from the research phase through non-clinical and CMC activities supporting IND into clinical development. Nanxin Pharmaceutical (688189) announced a few days ago that it intends to acquire 51% of Xingmeng Biotech through capital increase and cash payment.
This article is transferred from: https://www.itjuzi.com/merger/9514
This site is only for collection, and the copyright belongs to the original author.